Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Anzutresgene Autoleucel · IMA203

Cell therapy (TCR-T) · Kills target cells, directed at PRAME · developed by Immatics US

Phase 3 Most advanced trial
IMTX Developer
2 Registered trials

What is Anzutresgene Autoleucel?

Anzutresgene autoleucel is an autologous T-lymphocyte therapy genetically modified with a lentiviral vector encoding a T-cell receptor specific for PRAME, a tumor-associated antigen overexpressed in a variety of cancers. After infusion, the modified cells recognize PRAME-expressing cancer cells and mediate a cytotoxic T-lymphocyte response against them. It is studied in melanoma and other solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IMA203, anzu-cel
Drug type
Cell therapy (TCR-T)
Targets
PRAME (antigen)
Mechanism
Kills target cells, directed at PRAME
Pathways
cytotoxic T-lymphocyte-mediated immune response
Therapy area
Oncology
Developer
Immatics US, Inc. (IMTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06743126 Phase 3 Melanoma, Cutaneous Malignant Recruiting IMTX
NCT03686124 Phase 1/2 Refractory Cancer Recruiting IMTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancerMelanoma, Cutaneous MalignantRecurrent CancerRefractory CancerSolid Tumor, Adult

Other drugs acting on PRAME

More from Immatics US

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the IMTX page.

Follow IMTX, the company behind Anzutresgene Autoleucel

See IMTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.